Detailed price information for Intellia Thera CS (NTLA-Q) from The Globe and Mail including charting and trades.

Detailed price information for Intellia Thera CS (NTLA-Q) from The Globe and Mail including charting and trades.

According to DataM Intelligence, the global cell and gene therapy market reached a value of US$13.90 billion in 2024 and is ...

Contrarius Investment Management, an investment management company, released its third-quarter investor letter for the ...

Intellia Therapeutics, Inc. is rated Hold due to safety concerns after a patient death in its Phase 3 MAGNITUDE trial for ATTR-CM. NTLA's CRISPR/Cas9 gene editing offers potentially best-in-class, one ...

The FDA has issued a complete response letter for an oral selective glucocorticoid receptor antagonist under investigation ...

Though marketing and PR are different, they complement each other by working together to shape a brand’s narrative (PR) and drive business and sales goals (marketing). One tool once championed mostly ...

The Chicago Federal Reserve estimated on Tuesday that the U.S. unemployment rate remained at 4.6% in December, unchanged from November’s official rate. The Nove ...

Please provide your email address to receive an email when new articles are posted on . Around 6 months after lonvoguran ziclumeran infusion, researchers reported a –86% change in plasma kallikrein ...

The investment sets the stage for accelerated growth and value creation for ALLEGRIA. The funds will be used to progress its lead program towards pre-clinical candidates in support of nomination its ...

Turn Therapeutics Inc., operates as a pharmaceuticals company that develops drugs to treat diseases of the skin, nails, and eye. The company's delivery technology penetrates the skin and nails and ...

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat ...